FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385574549> ?p ?o ?g. }

• W4385574549 endingPage "100715" @default.
• W4385574549 startingPage "100715" @default.
• W4385574549 abstract "There is no real-world evidence regarding the association between beta-blocker use and mortality or cardiovascular outcomes in patients with obstructive sleep apnoea (OSA). We aimed to investigate the impact of beta-blocker use on all-cause mortality and cardiovascular diseases (CVDs) in patients with OSA.We conducted a target trial emulation study of 37,581 patients with newly diagnosed OSA from 1st January 2000 to 30th November 2021 using the IMRD-UK database (formerly known as the THIN database). We compared the treatment strategies of initiating beta-blocker treatment within one year versus non-beta-blocker treatment through the method of clone-censor-weight. Covariates, including patients' demographics, lifestyle, comorbidities, and recent medications, were measured and controlled. Patients were followed up for all-cause mortality or composite CVD outcomes (angina, myocardial infarction, stroke/transient ischaemic attack, heart failure, or atrial fibrillation). We estimated the five-year absolute risks, risk differences and risk ratio with 95% confidence intervals (CIs) with standardised, weighted pooled logistic regression, which is a discrete-time hazard model for survival analysis. Several sensitivity analyses were performed, including multiple imputation addressing the missing data.The median follow-up time was 4.1 (interquartile range, 1.9-7.8) years. The five-year absolute risk of all-cause mortality and CVD outcomes were 4.9% (95% CI, 3.8-6.0) and 13.0% (95% CI, 11.4-15.0) among beta-blocker users, and 4.0% (95% CI, 3.8-4.2) and 9.4% (95% CI, 9.1-9.7) among non-beta-blocker users, respectively. The five-year absolute risk difference and risk ratio between the two groups for all-cause mortality and CVD outcomes were 0.9% (95% CI, -0.2 to 2.1) and 1.22 (95% CI, 0.96-1.54), and 3.5% (95% CI, 2.1-5.5) and 1.37 (95% CI, 1.22-1.62), respectively. Findings were consistent across the sensitivity analyses.Beta-blocker treatment was associated with an increased risk of CVD and a trend for an increased risk of mortality among patients with OSA. Further studies are needed to confirm our findings.Innovation and Technology Commission of the Hong Kong Special Administration Region Government." @default.
• W4385574549 created "2023-08-05" @default.
• W4385574549 creator A5002130863 @default.
• W4385574549 creator A5028633730 @default.
• W4385574549 creator A5029858865 @default.
• W4385574549 creator A5031591258 @default.
• W4385574549 creator A5044684320 @default.
• W4385574549 creator A5056201384 @default.
• W4385574549 creator A5081246882 @default.
• W4385574549 date "2023-10-01" @default.
• W4385574549 modified "2023-09-30" @default.
• W4385574549 title "Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a population-based cohort study in target trial emulation framework" @default.
• W4385574549 cites W1605054078 @default.
• W4385574549 cites W1783190234 @default.
• W4385574549 cites W1964098393 @default.
• W4385574549 cites W1966836167 @default.
• W4385574549 cites W1973885323 @default.
• W4385574549 cites W2005565772 @default.
• W4385574549 cites W2008826528 @default.
• W4385574549 cites W2020001173 @default.
• W4385574549 cites W2023820468 @default.
• W4385574549 cites W2058307812 @default.
• W4385574549 cites W2068577110 @default.
• W4385574549 cites W2072481785 @default.
• W4385574549 cites W2084224010 @default.
• W4385574549 cites W2085879694 @default.
• W4385574549 cites W2093457132 @default.
• W4385574549 cites W2097796477 @default.
• W4385574549 cites W2135288867 @default.
• W4385574549 cites W2140817333 @default.
• W4385574549 cites W2143303021 @default.
• W4385574549 cites W2167472895 @default.
• W4385574549 cites W2287320059 @default.
• W4385574549 cites W2298338128 @default.
• W4385574549 cites W2546961642 @default.
• W4385574549 cites W2560099696 @default.
• W4385574549 cites W2619150349 @default.
• W4385574549 cites W2914456138 @default.
• W4385574549 cites W2939099777 @default.
• W4385574549 cites W2945183616 @default.
• W4385574549 cites W3022164665 @default.
• W4385574549 cites W3086207170 @default.
• W4385574549 cites W3092004864 @default.
• W4385574549 cites W3093590823 @default.
• W4385574549 cites W3118376758 @default.
• W4385574549 cites W3174049001 @default.
• W4385574549 cites W3215380543 @default.
• W4385574549 cites W4200347260 @default.
• W4385574549 cites W4320912456 @default.
• W4385574549 cites W4367673747 @default.
• W4385574549 doi "https://doi.org/10.1016/j.lanepe.2023.100715" @default.
• W4385574549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37601338" @default.
• W4385574549 hasPublicationYear "2023" @default.
• W4385574549 type Work @default.
• W4385574549 citedByCount "0" @default.
• W4385574549 crossrefType "journal-article" @default.
• W4385574549 hasAuthorship W4385574549A5002130863 @default.
• W4385574549 hasAuthorship W4385574549A5028633730 @default.
• W4385574549 hasAuthorship W4385574549A5029858865 @default.
• W4385574549 hasAuthorship W4385574549A5031591258 @default.
• W4385574549 hasAuthorship W4385574549A5044684320 @default.
• W4385574549 hasAuthorship W4385574549A5056201384 @default.
• W4385574549 hasAuthorship W4385574549A5081246882 @default.
• W4385574549 hasBestOaLocation W43855745491 @default.
• W4385574549 hasConcept C119060515 @default.
• W4385574549 hasConcept C126322002 @default.
• W4385574549 hasConcept C127413603 @default.
• W4385574549 hasConcept C156957248 @default.
• W4385574549 hasConcept C164705383 @default.
• W4385574549 hasConcept C207103383 @default.
• W4385574549 hasConcept C2778425758 @default.
• W4385574549 hasConcept C2778715236 @default.
• W4385574549 hasConcept C2779161974 @default.
• W4385574549 hasConcept C2780645631 @default.
• W4385574549 hasConcept C2908647359 @default.
• W4385574549 hasConcept C44249647 @default.
• W4385574549 hasConcept C500558357 @default.
• W4385574549 hasConcept C50382708 @default.
• W4385574549 hasConcept C71924100 @default.
• W4385574549 hasConcept C72563966 @default.
• W4385574549 hasConcept C78519656 @default.
• W4385574549 hasConcept C99454951 @default.
• W4385574549 hasConceptScore W4385574549C119060515 @default.
• W4385574549 hasConceptScore W4385574549C126322002 @default.
• W4385574549 hasConceptScore W4385574549C127413603 @default.
• W4385574549 hasConceptScore W4385574549C156957248 @default.
• W4385574549 hasConceptScore W4385574549C164705383 @default.
• W4385574549 hasConceptScore W4385574549C207103383 @default.
• W4385574549 hasConceptScore W4385574549C2778425758 @default.
• W4385574549 hasConceptScore W4385574549C2778715236 @default.
• W4385574549 hasConceptScore W4385574549C2779161974 @default.
• W4385574549 hasConceptScore W4385574549C2780645631 @default.
• W4385574549 hasConceptScore W4385574549C2908647359 @default.
• W4385574549 hasConceptScore W4385574549C44249647 @default.
• W4385574549 hasConceptScore W4385574549C500558357 @default.
• W4385574549 hasConceptScore W4385574549C50382708 @default.
• W4385574549 hasConceptScore W4385574549C71924100 @default.
• W4385574549 hasConceptScore W4385574549C72563966 @default.

• next